Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab
Authors:
Open Access
- 1 January 2012
- journal article
- review article
- Published by SAGE Publications in Clinical Medicine Insights: Ear, Nose and Throat
- Vol. 5, 1-16
Abstract
EGFR belongs to the ErbB family of receptor tyrosine kinases and is associated with worse prognosis in head and neck squamous cell carcinoma (HNSCC). Cetuximab is a monoclonal antibody to the extracellular domain of EGFR and inhibits its downstream actions via multiple mechanisms. Besides its proven efficacy in locally advanced and incurable HNSCC, cetuximab has the distinct advantage of having a relatively tolerable side effect profile and not potentiating radiation toxicity. Though therapies for advanced HNSCC are evolving, locoregional recurrence and/or distant metastases occur in a large percentage of patients. Though some patients can be salvaged with surgery or radiation therapy, the majority are incurable, and are treated palliatively with systemic therapy. In the setting of first line therapy for recurrent/metastatic HNSCC, the EXTREME trial provided level 1 evidence that cetuximab improves overall survival when combined with cisplatinum and 5 FU. Following progression on first line chemotherapy, several phase II trials suggest that cetuximab monotherapy is a reasonable choice in this setting. Future studies should concentrate on clinical and molecular markers that may allow more personalized approaches to treating HNSCC, and combining EGFR inhibitors with other agents in a synergistic approach.Keywords
This publication has 138 references indexed in Scilit:
- Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinomaHead & Neck, 2012
- The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab–bevacizumab–irradiation combination on head and neck cancer xenograftsOral Oncology, 2011
- Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neckHead & Neck, 2010
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patientsRadiotherapy and Oncology, 2009
- Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II studyThe Lancet Oncology, 2009
- Augmentation of Radiation Response by Panitumumab in Models of Upper Aerodigestive Tract CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for DimerizationCancer Cell, 2008
- Response to Therapy and Outcomes in Oropharyngeal Cancer Are Associated With Biomarkers Including Human Papillomavirus, Epidermal Growth Factor Receptor, Gender, and SmokingInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Structural basis for inhibition of the epidermal growth factor receptor by cetuximabCancer Cell, 2005
- EGFR and cancer prognosisEuropean Journal of Cancer, 2001